- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Peptide Cancer Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Peptide Cancer Vaccine market size is estimated to be worth US$ 562.7 million in 2021 and is forecast to a readjusted size of USD 1895.9 million by 2028 with a CAGR of 18.9% during review period. Breast Cancer accounting for % of the Peptide Cancer Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While ITK-1 segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, and Immatics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Peptide Cancer Vaccine market is split by Pipeline and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Pipeline and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Pipeline, covers
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Market segment by Application can be divided into
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
The key market players for global Peptide Cancer Vaccine market are listed below:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Peptide Cancer Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Peptide Cancer Vaccine, with price, sales, revenue and global market share of Peptide Cancer Vaccine from 2019 to 2022.
Chapter 3, the Peptide Cancer Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Peptide Cancer Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Pipeline and application, with sales market share and growth rate by pipeline, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Peptide Cancer Vaccine market forecast, by regions, pipeline and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide Cancer Vaccine.
Chapter 13, 14, and 15, to describe Peptide Cancer Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Peptide Cancer Vaccine Introduction
1.2 Market Analysis by Pipeline
1.2.1 Overview: Global Peptide Cancer Vaccine Revenue by Pipeline: 2017 Versus 2021 Versus 2028
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Peptide Cancer Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Global Peptide Cancer Vaccine Market Size & Forecast
1.4.1 Global Peptide Cancer Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Peptide Cancer Vaccine Sales in Volume (2017-2028)
1.4.3 Global Peptide Cancer Vaccine Price (2017-2028)
1.5 Global Peptide Cancer Vaccine Production Capacity Analysis
1.5.1 Global Peptide Cancer Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Peptide Cancer Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Peptide Cancer Vaccine Market Drivers
1.6.2 Peptide Cancer Vaccine Market Restraints
1.6.3 Peptide Cancer Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Boston Biomedical
2.1.1 Boston Biomedical Details
2.1.2 Boston Biomedical Major Business
2.1.3 Boston Biomedical Peptide Cancer Vaccine Product and Services
2.1.4 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Ultimovacs
2.2.1 Ultimovacs Details
2.2.2 Ultimovacs Major Business
2.2.3 Ultimovacs Peptide Cancer Vaccine Product and Services
2.2.4 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 BrightPath Biotherapeutics
2.3.1 BrightPath Biotherapeutics Details
2.3.2 BrightPath Biotherapeutics Major Business
2.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Product and Services
2.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 TapImmune
2.4.1 TapImmune Details
2.4.2 TapImmune Major Business
2.4.3 TapImmune Peptide Cancer Vaccine Product and Services
2.4.4 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Immatics
2.5.1 Immatics Details
2.5.2 Immatics Major Business
2.5.3 Immatics Peptide Cancer Vaccine Product and Services
2.5.4 Immatics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Sellas
2.6.1 Sellas Details
2.6.2 Sellas Major Business
2.6.3 Sellas Peptide Cancer Vaccine Product and Services
2.6.4 Sellas Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Imugene
2.7.1 Imugene Details
2.7.2 Imugene Major Business
2.7.3 Imugene Peptide Cancer Vaccine Product and Services
2.7.4 Imugene Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 VAXON Biotech
2.8.1 VAXON Biotech Details
2.8.2 VAXON Biotech Major Business
2.8.3 VAXON Biotech Peptide Cancer Vaccine Product and Services
2.8.4 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Generex Biotechnology
2.9.1 Generex Biotechnology Details
2.9.2 Generex Biotechnology Major Business
2.9.3 Generex Biotechnology Peptide Cancer Vaccine Product and Services
2.9.4 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 ISA Pharmaceuticals
2.10.1 ISA Pharmaceuticals Details
2.10.2 ISA Pharmaceuticals Major Business
2.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Product and Services
2.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 OncoTherapy Science
2.11.1 OncoTherapy Science Details
2.11.2 OncoTherapy Science Major Business
2.11.3 OncoTherapy Science Peptide Cancer Vaccine Product and Services
2.11.4 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Peptide Cancer Vaccine Breakdown Data by Manufacturer
3.1 Global Peptide Cancer Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Peptide Cancer Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Peptide Cancer Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Peptide Cancer Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Peptide Cancer Vaccine Manufacturer Market Share in 2021
3.5 Global Peptide Cancer Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Peptide Cancer Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Peptide Cancer Vaccine Market Size by Region
4.1.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Peptide Cancer Vaccine Revenue by Region (2017-2028)
4.2 North America Peptide Cancer Vaccine Revenue (2017-2028)
4.3 Europe Peptide Cancer Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Peptide Cancer Vaccine Revenue (2017-2028)
4.5 South America Peptide Cancer Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Peptide Cancer Vaccine Revenue (2017-2028)
5 Market Segment by Pipeline
5.1 Global Peptide Cancer Vaccine Sales in Volume by Pipeline (2017-2028)
5.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
5.3 Global Peptide Cancer Vaccine Price by Pipeline (2017-2028)
6 Market Segment by Application
6.1 Global Peptide Cancer Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Peptide Cancer Vaccine Revenue by Application (2017-2028)
6.3 Global Peptide Cancer Vaccine Price by Application (2017-2028)
7 North America by Country, by Pipeline, and by Application
7.1 North America Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
7.2 North America Peptide Cancer Vaccine Sales by Application (2017-2028)
7.3 North America Peptide Cancer Vaccine Market Size by Country
7.3.1 North America Peptide Cancer Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Peptide Cancer Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Pipeline, and by Application
8.1 Europe Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
8.2 Europe Peptide Cancer Vaccine Sales by Application (2017-2028)
8.3 Europe Peptide Cancer Vaccine Market Size by Country
8.3.1 Europe Peptide Cancer Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Peptide Cancer Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Pipeline, and by Application
9.1 Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
9.2 Asia-Pacific Peptide Cancer Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Peptide Cancer Vaccine Market Size by Region
9.3.1 Asia-Pacific Peptide Cancer Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Pipeline, and by Application
10.1 South America Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
10.2 South America Peptide Cancer Vaccine Sales by Application (2017-2028)
10.3 South America Peptide Cancer Vaccine Market Size by Country
10.3.1 South America Peptide Cancer Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Peptide Cancer Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Pipeline, and by Application
11.1 Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
11.2 Middle East & Africa Peptide Cancer Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Peptide Cancer Vaccine Market Size by Country
11.3.1 Middle East & Africa Peptide Cancer Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Peptide Cancer Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Peptide Cancer Vaccine
12.3 Peptide Cancer Vaccine Production Process
12.4 Peptide Cancer Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Peptide Cancer Vaccine Typical Distributors
13.3 Peptide Cancer Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Peptide Cancer Vaccine Revenue by Pipeline, (USD Million), 2017 & 2021 & 2028
Table 2. Global Peptide Cancer Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Boston Biomedical Basic Information, Manufacturing Base and Competitors
Table 4. Boston Biomedical Major Business
Table 5. Boston Biomedical Peptide Cancer Vaccine Product and Services
Table 6. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Ultimovacs Basic Information, Manufacturing Base and Competitors
Table 8. Ultimovacs Major Business
Table 9. Ultimovacs Peptide Cancer Vaccine Product and Services
Table 10. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. BrightPath Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 12. BrightPath Biotherapeutics Major Business
Table 13. BrightPath Biotherapeutics Peptide Cancer Vaccine Product and Services
Table 14. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. TapImmune Basic Information, Manufacturing Base and Competitors
Table 16. TapImmune Major Business
Table 17. TapImmune Peptide Cancer Vaccine Product and Services
Table 18. TapImmune Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Immatics Basic Information, Manufacturing Base and Competitors
Table 20. Immatics Major Business
Table 21. Immatics Peptide Cancer Vaccine Product and Services
Table 22. Immatics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Sellas Basic Information, Manufacturing Base and Competitors
Table 24. Sellas Major Business
Table 25. Sellas Peptide Cancer Vaccine Product and Services
Table 26. Sellas Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Imugene Basic Information, Manufacturing Base and Competitors
Table 28. Imugene Major Business
Table 29. Imugene Peptide Cancer Vaccine Product and Services
Table 30. Imugene Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. VAXON Biotech Basic Information, Manufacturing Base and Competitors
Table 32. VAXON Biotech Major Business
Table 33. VAXON Biotech Peptide Cancer Vaccine Product and Services
Table 34. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Generex Biotechnology Basic Information, Manufacturing Base and Competitors
Table 36. Generex Biotechnology Major Business
Table 37. Generex Biotechnology Peptide Cancer Vaccine Product and Services
Table 38. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. ISA Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 40. ISA Pharmaceuticals Major Business
Table 41. ISA Pharmaceuticals Peptide Cancer Vaccine Product and Services
Table 42. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. OncoTherapy Science Basic Information, Manufacturing Base and Competitors
Table 44. OncoTherapy Science Major Business
Table 45. OncoTherapy Science Peptide Cancer Vaccine Product and Services
Table 46. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Global Peptide Cancer Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 48. Global Peptide Cancer Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 49. Market Position of Manufacturers in Peptide Cancer Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 50. Global Peptide Cancer Vaccine Production Capacity by Company, (K Doses): 2020 VS 2021
Table 51. Head Office and Peptide Cancer Vaccine Production Site of Key Manufacturer
Table 52. Peptide Cancer Vaccine New Entrant and Capacity Expansion Plans
Table 53. Peptide Cancer Vaccine Mergers & Acquisitions in the Past Five Years
Table 54. Global Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 55. Global Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 56. Global Peptide Cancer Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 57. Global Peptide Cancer Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 58. Global Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 59. Global Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 60. Global Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (USD Million)
Table 61. Global Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (USD Million)
Table 62. Global Peptide Cancer Vaccine Price by Pipeline (2017-2022) & (USD/Dose)
Table 63. Global Peptide Cancer Vaccine Price by Pipeline (2023-2028) & (USD/Dose)
Table 64. Global Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 65. Global Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 66. Global Peptide Cancer Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 67. Global Peptide Cancer Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 68. Global Peptide Cancer Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 69. Global Peptide Cancer Vaccine Price by Application (2023-2028) & (USD/Dose)
Table 70. North America Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 71. North America Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 72. North America Peptide Cancer Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 73. North America Peptide Cancer Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 74. North America Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 75. North America Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 76. North America Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 77. North America Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 78. Europe Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 79. Europe Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 80. Europe Peptide Cancer Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 81. Europe Peptide Cancer Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 82. Europe Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 83. Europe Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 84. Europe Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 85. Europe Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 86. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 87. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 88. Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 89. Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 90. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 91. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 92. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 93. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 94. South America Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 95. South America Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 96. South America Peptide Cancer Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 97. South America Peptide Cancer Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 98. South America Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 99. South America Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 100. South America Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 101. South America Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 102. Middle East & Africa Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 103. Middle East & Africa Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 104. Middle East & Africa Peptide Cancer Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 105. Middle East & Africa Peptide Cancer Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 106. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 107. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 108. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 109. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 110. Peptide Cancer Vaccine Raw Material
Table 111. Key Manufacturers of Peptide Cancer Vaccine Raw Materials
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Peptide Cancer Vaccine Typical Distributors
Table 115. Peptide Cancer Vaccine Typical Customers
List of Figures
Figure 1. Peptide Cancer Vaccine Picture
Figure 2. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline in 2021
Figure 3. ITK-1
Figure 4. GRN-1201
Figure 5. TPIV200
Figure 6. TPIV110
Figure 7. UV1
Figure 8. Galinpepimut-S
Figure 9. TARP 27-35
Figure 10. HER-Vaxx
Figure 11. Vx-001
Figure 12. Others
Figure 13. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2021
Figure 14. Breast Cancer
Figure 15. Lung Cancer
Figure 16. Melanoma
Figure 17. Prostate Cancer
Figure 18. Others
Figure 19. Global Peptide Cancer Vaccine Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 20. Global Peptide Cancer Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 21. Global Peptide Cancer Vaccine Sales (2017-2028) & (K Doses)
Figure 22. Global Peptide Cancer Vaccine Price (2017-2028) & (USD/Dose)
Figure 23. Global Peptide Cancer Vaccine Production Capacity (2017-2028) & (K Doses)
Figure 24. Global Peptide Cancer Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 25. Peptide Cancer Vaccine Market Drivers
Figure 26. Peptide Cancer Vaccine Market Restraints
Figure 27. Peptide Cancer Vaccine Market Trends
Figure 28. Global Peptide Cancer Vaccine Sales Market Share by Manufacturer in 2021
Figure 29. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturer in 2021
Figure 30. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 31. Top 3 Peptide Cancer Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 32. Top 6 Peptide Cancer Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 33. Global Peptide Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Region (2017-2028)
Figure 35. North America Peptide Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 36. Europe Peptide Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 37. Asia-Pacific Peptide Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 38. South America Peptide Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 39. Middle East & Africa Peptide Cancer Vaccine Revenue (2017-2028) & (USD Million)
Figure 40. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 41. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
Figure 42. Global Peptide Cancer Vaccine Price by Pipeline (2017-2028) & (USD/Dose)
Figure 43. Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Global Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 45. Global Peptide Cancer Vaccine Price by Application (2017-2028) & (USD/Dose)
Figure 46. North America Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 47. North America Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 48. North America Peptide Cancer Vaccine Sales Market Share by Country (2017-2028)
Figure 49. North America Peptide Cancer Vaccine Revenue Market Share by Country (2017-2028)
Figure 50. United States Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Canada Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Mexico Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 54. Europe Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 55. Europe Peptide Cancer Vaccine Sales Market Share by Country (2017-2028)
Figure 56. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2017-2028)
Figure 57. Germany Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. France Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. United Kingdom Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Russia Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Italy Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 63. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 64. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 65. Asia-Pacific Peptide Cancer Vaccine Revenue Market Share by Region (2017-2028)
Figure 66. China Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Japan Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Korea Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. India Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Southeast Asia Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Australia Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South America Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 73. South America Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 74. South America Peptide Cancer Vaccine Sales Market Share by Country (2017-2028)
Figure 75. South America Peptide Cancer Vaccine Revenue Market Share by Country (2017-2028)
Figure 76. Brazil Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Argentina Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 79. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 80. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Region (2017-2028)
Figure 81. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Region (2017-2028)
Figure 82. Turkey Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Egypt Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. Saudi Arabia Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. South Africa Peptide Cancer Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine in 2021
Figure 87. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 88. Peptide Cancer Vaccine Industrial Chain
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
Figure 90. Methodology
Figure 91. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
